VYNE
VYNE Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$28.56
+0.00%Price chart
Jul 24Jul 29Aug 3Aug 6Aug 11Aug 14Aug 19Aug 24
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.4x
Market Cap
$19.07M
MomentumView details →
1D Return
+0.00%
YTD Return
+36.16%
RSI (14)
52.4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.4x
Market Cap
$19.07M
RSI (14)
52.4
MomentumView details →
1D Return
+0.00%
YTD Return
+36.16%
SummaryUpdated Jun 1, 2026
VYNE Therapeutics Inc. (NASDAQ:VYNE) is a pharmaceutical company founded in 2003 and headquartered in Bridgewater, New Jersey. Originally known as Menlo Therapeutics Inc., the company rebranded to VYNE Therapeutics in September 2020. The company specializes in developing therapeutic treatments for immuno-inflammatory conditions, with a particular focus on dermatological disorders such as acne and atopic dermatitis. As a clinical-stage biotechnology company, VYNE has advanced several drug candidates through various phases of clinical trials, with its lead product having completed Phase III trials for acne treatment.
Similar companies
Latest newsMore news →
VYNE Therapeutics announced a 1-for-50 reverse stock split and a special dividend in connection with its proposed merger with Yarrow Bioscience.45d agoVYNE Therapeutics declared a special cash dividend of approximately $16.5 million ($0.38 per share) in connection with its proposed merger with Yarrow Bioscience.56d ago